Eli Lilly invests heavily in the British biotech scene

The American pharmaceutical giant Eli Lilly has ambitious plans to promote British biotechnology. With an investment of 279 million pounds, equivalent to 364 million US dollars, the company aims to support innovative biotech firms in the United Kingdom while simultaneously examining the effects of its leading medications for diabetes and obesity on the healthcare system. A key component of this initiative is the establishment of a Lilly Gateway Lab in the UK, for which Eli Lilly has earmarked up to 204 million pounds. This facility is intended to provide emerging biotech companies with access to Lilly’s extensive expertise, state-of-the-art laboratory facilities, and potential financial support. In addition to infrastructure investment, a five-year study will be initiated to investigate the real-world application of the drug Tirzepatide. Known as Mounjaro in the US for diabetes treatment and Zepbound for weight reduction, the drug is to be closely examined regarding its impact on healthcare resource utilization.